Trial Profile
A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs CD40L GVAX (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2018 Planned End Date changed from 31 Dec 2020 to 1 Jul 2020.
- 25 Jun 2018 Planned primary completion date changed from 31 Dec 2019 to 1 Jul 2019.
- 25 Jun 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.